Komori
TAUNS Laboratories (197A) · InitiativeFirst statedLatest Earnings presentation (2026-08-13): "Advanced"

Commercialization and performance improvements for new antibodies, Accu-Lead and other products

First written in FY2024. 4 of 5 entries say "Advanced", first in 2026-05-14. Latest entry: 2026-08-13.

5entries
3years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024Advanced2026-05-14 – 2026-08-132024: 120242025: 020252026: 42026
Same theme, other companies
Commercialization and Performance Improvement of the New Antibody and アキュリード ProductsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Moved together

"Expansion of Sales Channels Through Collaboration with Sales Representatives, Agencies and Pharmaceutical Companies" moved the same way as this thread, in the same document, in 2 of its 5 moves.

2222★1234
  1. ★This thread
  2. 1Expansion of Sales Channels Through Collaboration with Sales Representatives, Agencies and Pharmaceutical Companies2×
  3. 2Dependence on Sales of COVID-19-Related Products2×
  4. 3Stable, Sustained Dividends Based on a Payout Ratio of Approximately 30%2×
  5. 4Productivity Gains Through a New Core Business System and Medical Data Platform2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet. It last moved in the Earnings presentation of 2026-08-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.